Top line contracting.
−2.8% YoY versus −6.1% prior. 3y CAGR −1.5%.
−2.8%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $1.4B
Fundamentals as of 2026-03-28
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
Bottom line: PRGO currently has no legendary investor models qualifying — see /stock/PRGO/valuation for the per-model breakdown, but earns a D sector grade (43/100) in Healthcare. Use the per-tab analysis to form your own view. Drill into the valuation breakdown and sector ranking for the full picture.
Financial data for PRGO is limited. Full statements are available below.
Financial story
Financial data for PRGO is limited. Full statements are available below.
How does PRGO compare?
0 of 6 legendary investor models rate PRGO a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Perrigo Company plc's fair value depends on which model you trust. See the per-investor fair-value table in the valuation tab.
PRGO's valuation depends on which lens you apply. Sector context and per-investor signals are in the valuation tab.
PRGO and INSP differ on P/E, ROE, and revenue growth. See the full PRGO vs INSP compare matrix.
Investor verdicts for PRGO are listed in the valuation tab. Per-model fair value and reasoning are in the valuation tab.
PRGO's P/E is shown in the financials tab. 5-year P/E history is in the financials tab.
See exactly where PRGO ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingPRGO sits at #81 in Healthcare with a D grade (43/100).
−2.8% YoY versus −6.1% prior. 3y CAGR −1.5%.
−2.8%Net margin −33.5% versus −3.9% prior (−29.6pp). Operating 8.1%.
−33.5%P/E 442.6x — 513% above the 5y median of 72.2x. Forward 4.8x hints at EPS expansion next year.
442.6x